^
    almost2years
    The synovial and systemic pharmacokinetics and pharmacodynamics of intra-articular administration of the CSF1 receptor antibody AMB-05X in a phase II proof-of-concept trial in tenosynovial giant cell tumor (ESMO 2022)
    CSF1 levels in both compartments achieved a plateau, indicative of full receptor engagement, early in the treatment period. Conclusions The AMB-05X PK and PD results support expansion of the clinical development of AMB-05X in TGCT with IA treatment at a comfortable interval of once-monthly or less.
    P2 data • PK/PD data
    |
    CSF1R (Colony stimulating factor 1 receptor)
    |
    AMB-05X
    over3years
    Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. (PubMed, J Immunother Cancer)
    The recommended combination dose of 1100 mg AMG 820 plus 200 mg pembrolizumab had an acceptable safety profile. Although pharmacodynamic effects were observed, antitumor activity was insufficient for further evaluation of this combination in selected patient populations.
    Journal • Combination therapy • PD(L)-1 Biomarker
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CSF1R (Colony stimulating factor 1 receptor)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • AMB-05X